News & Events

Press Releases

On the 28th March 2022, OncoArendi changed its name to Molecure

Molecure Third Quarter 2022 Pipeline Highlights and Financial Results

31 October 2022

Molecure reports continued pipeline momentum for 6 months ended 30th June 2022

29 September 2022

Molecure announces filing of Clinical Trial Application with Polish regulator for OATD-02, a novel dual arginase inhibitor being developed for the treatment of cancer

11 August 2022

Molecure to regain worldwide rights to dual chitinase inhibitor OATD-01

23 June 2022

OncoArendi Therapeutics Reports Continued Strategic and Operational Momentum for 12 Months ended 31 December 2021

25 March 2022

OncoArendi Therapeutics Announces a License Option Agreement with University of Michigan

11 March 2022

Events & Presentations

R&D Day Presentation, 07.12.2022

7 December 2022

Fibrosis and Tissue Repair: From Molecules and Mechanics to Therapeutic Approaches – February 19-23, 2020 | Victoria, BC, Canada

27 February 2020

EFMC-ASMC’19 – September 1-5, 2019 | Athens, Greece

11 September 2019

ACS National Meeting & Expo – August 25 – 29, 2019 | San Diego, CA

4 September 2019

ATS- International Conference – Dallas, 17-22.05.2019

22 May 2019

EFMC – YMCS – Young Medicinal Chemist Symposium – Ljubljana 02-06.09.2018

17 September 2018
This site is registered on wpml.org as a development site.